Crisaborole 2 % Topical Ointment + PF-07038124 0.01% topical ointment + Vehicle
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vitiligo
Conditions
Vitiligo
Trial Timeline
Sep 7, 2022 → Apr 30, 2024
NCT ID
NCT05298033About Crisaborole 2 % Topical Ointment + PF-07038124 0.01% topical ointment + Vehicle
Crisaborole 2 % Topical Ointment + PF-07038124 0.01% topical ointment + Vehicle is a phase 2 stage product being developed by Pfizer for Vitiligo. The current trial status is completed. This product is registered under clinical trial identifier NCT05298033. Target conditions include Vitiligo.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05298033 | Phase 2 | Completed |
Competing Products
20 competing products in Vitiligo